Home/Pipeline/SBX 1977

SBX 1977

Wound Healing

Early-stage ClinicalActive

Key Facts

Indication

Wound Healing

Phase

Early-stage Clinical

Status

Active

Company

Stramsen Biotech

About Stramsen Biotech

Stramsen Biotech is an early-stage, private biotech firm pioneering a plant-based drug discovery and development platform. It boasts a robust pipeline of 33 drug candidates, with 11 in early-stage clinical trials, targeting major therapeutic areas including oncology, cardiovascular disease, HIV, and diabetes. The company claims a $19 billion valuation from a third-party appraisal and is backed by lead investor GEM Global Yield LLC SCS, positioning it for significant growth as it advances candidates toward FDA submissions.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Diseases Infectious Disease (HIV)Metabolic Disorders (Diabetes)Neurological Disorders Musculoskeletal Disorders (Arthritis)Urology Wound Care Nephrology

Other Wound Healing Drugs

Drug	Company	Phase	Status
CYWC628	FibroBiologics	Discovery	Active
BXT-25	BioXyTran	Preclinical	Active
Advanced Wound Care Program	Ionic Pharmaceuticals	Research	Active
Wound Care Formulations	MediCell Technologies	Commercial	Active
StroMel™ (Planned)	Akan Biosciences	Planned	Active
MRG-001	MedRegen	Phase 2	Active (Study Completed, Data Pending)
CordLining Stem Cell Therapy	CellResearchCorp	Phase 1	Active
ABCcolla® Collagen Matrix	ACRO Biomedical	Commercial	Active